Canaccord Genuity Maintains a 'Buy' on Hologic (HOLX); Looking for a Dip
Tweet Send to a FriendGet Alerts HOLX Hot Sheet
Price: $21.09 +1.05%
Rating Summary:
16 Buy, 6 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
16 Buy, 6 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade HOLX Now!
Canaccord Genuity maintains a 'Buy' on Hologic (NASDAQ: HOLX) price target of $23.00 (from $24.00).
Analyst, Jason R. Mills, said, "We maintain our rating and adjust our PT ahead of the closing of the Gen-Probe (Nasdaq: GPRO) acquisition. We favor the potential outputs of the acquisition– namely sales synergies and potential for cash flow accretion and growth augmentation. We also remain constructive regarding growth potential of the Breast Health business – namely potential inflection point with 3D Tomo over the next 18-24 months. That said, we have some concern regarding integration performance, notwithstanding our belief that GPRO is a best-in-class asset that could augment long-term FCF growth. While we would be buyers if shares dip into the $17 range, we would wait to be more constructive until we see the initial performance and projections for the combined company, which will be inherent in FQ4 results (Oct)."
For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.
Shares of Hologic closed at $18.26 yesterday, with a 52 week range of $13.90-$22.16.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Jason R. Mills, said, "We maintain our rating and adjust our PT ahead of the closing of the Gen-Probe (Nasdaq: GPRO) acquisition. We favor the potential outputs of the acquisition– namely sales synergies and potential for cash flow accretion and growth augmentation. We also remain constructive regarding growth potential of the Breast Health business – namely potential inflection point with 3D Tomo over the next 18-24 months. That said, we have some concern regarding integration performance, notwithstanding our belief that GPRO is a best-in-class asset that could augment long-term FCF growth. While we would be buyers if shares dip into the $17 range, we would wait to be more constructive until we see the initial performance and projections for the combined company, which will be inherent in FQ4 results (Oct)."
For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.
Shares of Hologic closed at $18.26 yesterday, with a 52 week range of $13.90-$22.16.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- UBS Survey Shows Signs of Strength for Gilead's (GILD) TAF
- Goldman Sachs Upgrades Ruckus Wireless (RKUS) to Buy, 'Pullback Creates Opportunity'
Create E-mail Alert Related Categories
Analyst Comments, Mergers and AcquisitionsRelated Entities
Canaccord Genuity
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
